Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Polidocanol (1%) Microfoam (Varisolve)
Polidocanol Microfoam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Polidocanol (1%) Microfoam (Varisolve) |
| Name | Type | Description |
|---|---|---|
| Polidocanol (1%) Microfoam (Varisolve) | DRUG | Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein. |
| Endovenous Microfoam Occlusion | PROCEDURE | Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries. |
Inclusion Criteria: * Males and females aged 18 to 60 with severe varicose veins, CEAP classes 3, 4 and 5 (CEAP is a classification and grading system for chronic venous disease) * Saphenofemoral junction (SFJ) incompetence. Retrograde blood flow in the GSV, greater than or equal to 1.0 second demo...
Polidocanol Microfoam is an investigational small molecule therapy being developed for the treatment of varicose veins. It is a foam formulation of polidocanol, also known as polidocanol (1%) microfoam or Varisolve, and is administered as part of a procedure. It is in Phase 2 clinical development.
Polidocanol Microfoam is being studied for the treatment of varicose veins, a cardiovascular condition. The clinical program has evaluated its use in patients with varicose veins, including a safety study in patients with a right-to-left cardiac shunt. It is not yet approved and remains investigational.
Polidocanol Microfoam is developed by Boston Scientific Corporation, which trades on the New York Stock Exchange under the ticker BSX. The company is the sponsor of the clinical program evaluating the agent for varicose veins.
Polidocanol Microfoam is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. One Phase 2 trial has been completed, and no trials are currently active.
Polidocanol Microfoam has been evaluated in one completed Phase 2 trial, NCT00442364, titled a safety study of the Varisolve procedure for treatment of varicose veins in patients with right-to-left cardiac shunt. The trial enrolled 60 patients in the United States and has completed.
Yes. Polidocanol Microfoam is also known as polidocanol (1%) microfoam, or Varisolve. These names refer to the same investigational product developed by Boston Scientific Corporation for the treatment of varicose veins.